


Group 1 - The core viewpoint of the article highlights the significant market activity surrounding Jinfang Pharmaceutical-B (02595), including a stock transfer valued at HKD 437 million, representing 3.42% of the company [1] - On September 19, Jinfang Pharmaceutical-B was listed on the Hong Kong Stock Exchange, with its stock price reaching a peak of HKD 50.20, an increase of 146.20% from the issue price, and closing with a gain of 106.47%, bringing its market capitalization close to HKD 15 billion [1] - Jinfang Pharmaceutical focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes eight candidate products, five of which are in clinical development, including two core products GFH925 and GFH375 [1]